Edesa Biotech ((EDSA)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The JUST BREATHE study, officially titled ‘Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients With Acute Respiratory Distress Syndrome (ARDS),’ aims to evaluate the safety and efficacy of innovative therapies for ARDS. This trial is significant as it explores multiple therapeutic options for a critical condition affecting hospitalized patients.
The study is testing paridiprubart, an experimental drug administered as a single IV dose, against a placebo. The intervention aims to improve outcomes for ARDS patients by targeting host-directed therapeutic pathways.
This Phase 2 trial employs a randomized, parallel, and triple-masked design, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either the experimental drug or a placebo, with both participants and providers blinded to the treatment allocation.
The study began on June 10, 2025, with primary completion expected within 90 days per participant. The last update was submitted on July 10, 2025. These dates are crucial for tracking the study’s progress and potential impact.
For Edesa Biotech, this study could influence stock performance positively if results show efficacy, as ARDS remains a significant unmet medical need. The involvement of industry giants like Genentech and InflaRx highlights the competitive landscape and potential market interest.
The study is ongoing, with further details available on the ClinicalTrials portal.